

Special Issue

Immunity and Gastrointestinal Cancer

Message from the Guest Editor

Immunotherapy approaches have recently provided great benefits to patients affected across the spectrum of gastrointestinal cancers. However, the benefits are still not uniform for all patients, and predictive biomarkers remain limited. To date, only inhibitors of the PD-1 or CTLA-4 immune-checkpoint pathways have garnered regulatory approval in gastrointestinal cancers, highlighting the potential that further research into novel immunotherapy strategies and/or immune pathways may yield more positive outcomes for patients. We are pleased to invite the submission of works covering clinical, translational, and/or basic science topics which contribute to an increased understanding of the intersection between immunity and gastrointestinal cancers. This Special Issue aims to cover multiple facets of both preclinical and clinical research harnessing immune mechanisms to augment anti-tumor responses in all cancers of the gastrointestinal tract. This includes cancers affecting the esophagus, gastroesophageal junction, stomach, small bowel, liver, pancreas, colon, rectum, and anal canal.

Guest Editor

Dr. Joseph Chao

Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA 91010, USA

Deadline for manuscript submissions

closed (25 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/108065

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)